Bosh sahifaTMO • NYSE
add
Thermo Fisher Scientific
Yopilish kursi
565,32 $
Kunlik diapazon
554,20 $ - 569,40 $
Yillik diapazon
385,46 $ - 610,97 $
Bozor kapitalizatsiyasi
212,62 mlrd USD
Oʻrtacha hajm
2,33 mln
Narx/foyda
32,70
Dividend daromadliligi
0,30%
Asosiy maydon
NYSE
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 11,12 mlrd | 4,94% |
Joriy xarajat | 2,45 mlrd | 0,99% |
Sof foyda | 1,62 mlrd | -0,86% |
Sof foyda marjasi | 14,53 | -5,53% |
Har bir ulushga tushum | 5,79 | 9,66% |
EBITDA | 2,82 mlrd | 5,75% |
Amaldagi soliq stavkasi | 11,32% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 3,55 mlrd | -46,64% |
Jami aktivlari | 103,02 mlrd | 2,65% |
Jami passivlari | 51,87 mlrd | 1,17% |
Umumiy kapital | 51,15 mlrd | — |
Tarqatilgan aksiyalar | 375,71 mln | — |
Narxi/balansdagi bahosi | 4,16 | — |
Aktivlardan daromad | 5,25% | — |
Kapitaldan daromad | 6,21% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 1,62 mlrd | -0,86% |
Operatsiyalardan naqd pul | 2,24 mlrd | 3,37% |
Sarmoyadan naqd pul | -4,12 mlrd | -15,23% |
Moliyadan naqd pul | -632,00 mln | 46,89% |
Naqd pulning sof oʻzgarishi | -2,59 mlrd | -6,80% |
Boʻsh pul | 1,47 mlrd | -21,49% |
Haqida
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain. Wikipedia
Tashkil etilgan
1956
Sayt
Xodimlar soni
125 000
